Benefits, Safety, and Adjunct Modality Prevalences of Long-Term Botulinum Toxin Injections for Cervical Dystonia and Myofascial Neck Pain: A Retrospective Cohort Study
Open Access
- 1 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Pain Research
- Vol. ume 13, 1297-1304
- https://doi.org/10.2147/jpr.s254032
Abstract
Introduction: There is a paucity of long-term treatment benefit and safety data of botulinum toxin A (BTX-A) for cervical dystonia (CD) and myofascial neck pain syndrome (MPS). Additionally, the prevalence of adjunct modality uses during this period is unknown despite evolving practices. Objective: To assess and compare treatment benefit, safety, and adjunct modality prevalences of long-term BTX-A injections between CD and MPS patients. Design: Retrospective cohort study. Setting: Private practice tertiary care clinics in Toronto. Patients: Convenience sample of 37 (52.9%) CD and 33 (47.1%) MPS patients treated for a mean±SD duration of 7.2± 4.3 and 8.3± 4.7 years, respectively. Interventions: BTX-A injections administered at least once yearly, for a duration longer than 1 year. Main Outcome Measures: Toronto Western Spasmodic Torticollis Rating Scales (TWSTRS) for disability and pain, Patient Global Impression of Change (PGIC) score, time to peak effect, duration of total response, adverse effects, and prevalence of adjunct modalities. Results: CD patients experienced improvements in TWSTRS disability (17.57± 6.79 to 9.81± 4.35, p< 0.001) and pain (14.61± 3.08 to 9.05± 3.49, p< 0.001) scores as well as PGIC score (52.00%± 23.60% to 64.80%± 23.60%, p=0.007). MPS patients experienced improvements in TWSTRS disability (15.86± 7.70 to 10.07± 7.01, p=0.01) and pain (15.25± 4.09 to 10.85± 4.49, p=0.01) scores. In both cohorts, there were no changes in time to peak effect and duration of total response. Adverse effects were minimal and self-limiting. Prevalences of adjunct modalities used by CD versus MPS patients were 28.13% versus 50.00% for anesthetic procedures, 23.08% versus 15.38% for image-guidance, 65.71% versus 56.25% for pectoralis minor injections, and 47.06% versus 53.13% for cannabis-use. Conclusion: There were demonstrated and comparable treatment benefit, safety, and adjunct modality prevalences. Our study is the first to demonstrate that long-term BTX-A injections for MPS, although commonly used off-label, can be effective and safe.Keywords
This publication has 44 references indexed in Scilit:
- Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Botulinum Toxin for the Treatment of Myofascial Pain Syndromes Involving the Neck and Back: A Review from a Clinical PerspectiveEvidence-Based Complementary and Alternative Medicine, 2013
- Long-Term Efficacy and Safety of Botulinum Toxin Injections in DystoniaToxins, 2013
- Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapyJournal of Neural Transmission, 2012
- Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trialBasal Ganglia, 2011
- A Double-Blind, Controlled, Randomized Trial to Evaluate the Efficacy of Botulinum Toxin for the Treatment of Lumbar Myofascial Pain in HumansRegional Anesthesia & Pain Medicine, 2010
- Botulinum toxinIndian Journal of Dermatology, 2010
- Treatment strategies for dystoniaExpert Opinion on Pharmacotherapy, 2009
- Long‐term follow‐up of cervical dystonia patients treated with botulinum toxin AMovement Disorders, 2003
- A Dramatic Response to Inhaled Cannabis in a Woman with Central Thalamic Pain and DystoniaJournal of Pain and Symptom Management, 2002